Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology
Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling results from its latest pre-pivotal clinical trial for its next-generation continuous glucose monitoring (CGM) system.
Just a few years ago, children with type 1 diabetes reported to the school nurse several times a day to get a finger pricked ...
This study reinforces the significance of intensive glycaemic control and is a paradigm shift in managing the disease and its ...
Trinity stock is trading higher on Tuesday after the company announced results from its pre-pivotal clinical trial for its ...
Monitoring of the body's blood sugar is essential to the treatment of diabetes. But getting effective glucose readings has long been a challenge, according to UW Medicines Diabetes Institute professor ...
French shipping and logistics group CMA CGM will continue to avoid the Red Sea even though it considers the region is more ...
CMA CGM-backed windship developer Neoline has finally got its first vessel in the water. The 1,200-lane meter, 265 teu Neoliner Origin is a dedicated commercial ro-ro vessel that is primarily powered ...
The three vans sit on a new 800-volt platform that enables 20-minute charging top-ups to 80%. Flexis announced it will sell ...
Flexis has unveiled three new commercial vans, which will be launched in Europe next year. They’re based on an electric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback